Literature DB >> 8403068

Circadian neuroendocrine role in age-related changes in body fat stores and insulin sensitivity of the male Sprague-Dawley rat.

A H Cincotta1, B C Schiller, R J Landry, S J Herbert, W R Miers, A H Meier.   

Abstract

A role for circadian neuroendocrine rhythms in the age-related development of obesity and insulin resistance was investigated in the male Sprague-Dawley rat. The phases and amplitudes of the plasma rhythms of several metabolic hormones (i.e., corticosterone, prolactin, insulin, and triiodothyronine) differed in lean, insulin-sensitive (3-week-old rats), insulin-resistant (8-week-old rats) and obese, insulin-resistant (44-week-old rats) animals. Simulation of the daily rhythms of endogenous corticosterone and prolactin by daily injections of the hormones at times corresponding to the peak levels found in 3-week-old rats reversed age-related increases in insulin resistance and body fat in older (5-6-month-old) rats. Ten such daily injections of corticosterone and prolactin in 12-14-week-old rats produced long-term reductions in body fat stores (30%), plasma insulin concentration (40%), and insulin resistance (60%) (determined by a glucose tolerance test) measured 11-14 weeks after the treatment. Alterations in circadian neuroendocrine rhythms may account for age-related changes in carbohydrate and lipid metabolism in the male Sprague-Dawley rat, and resetting of these rhythms by appropriately timed daily injections of corticosterone and prolactin may help maintain metabolism characteristic of younger animals.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8403068     DOI: 10.1080/07420529309059707

Source DB:  PubMed          Journal:  Chronobiol Int        ISSN: 0742-0528            Impact factor:   2.877


  12 in total

Review 1.  Aging in the circadian system: considerations for health, disease prevention and longevity.

Authors:  Erin M Gibson; Wilbur P Williams; Lance J Kriegsfeld
Journal:  Exp Gerontol       Date:  2008-05-23       Impact factor: 4.032

Review 2.  Importance of circadian timing for aging and longevity.

Authors:  Victoria A Acosta-Rodríguez; Filipa Rijo-Ferreira; Carla B Green; Joseph S Takahashi
Journal:  Nat Commun       Date:  2021-05-17       Impact factor: 14.919

3.  Nature's Timepiece-Molecular Coordination of Metabolism and Its Impact on Aging.

Authors:  Andrea Bednářová; Dalibor Kodrík; Natraj Krishnan
Journal:  Int J Mol Sci       Date:  2013-01-31       Impact factor: 5.923

4.  Bromocriptine mesylate: Food and Drug Administration approved new approach in therapy of non-insulin dependant diabetes mellitus with poor glycemic control.

Authors:  Yogendra Keche
Journal:  J Pharm Bioallied Sci       Date:  2010-04

5.  Bromocriptine in type 2 diabetes mellitus.

Authors:  C Shivaprasad; Sanjay Kalra
Journal:  Indian J Endocrinol Metab       Date:  2011-07

6.  Disease and Degeneration of Aging Neural Systems that Integrate Sleep Drive and Circadian Oscillations.

Authors:  Kristan G Singletary; Nirinjini Naidoo
Journal:  Front Neurol       Date:  2011-10-24       Impact factor: 4.003

7.  A randomized, double-blind, placebo-controlled trial to assess safety and tolerability during treatment of type 2 diabetes with usual diabetes therapy and either Cycloset or placebo.

Authors:  Richard E Scranton; J Michael Gaziano; Dean Rutty; Michael Ezrokhi; Anthony Cincotta
Journal:  BMC Endocr Disord       Date:  2007-06-25       Impact factor: 2.763

8.  Neuroendocrine and metabolic components of dopamine agonist amelioration of metabolic syndrome in SHR rats.

Authors:  Michael Ezrokhi; Shuqin Luo; Yelena Trubitsyna; Anthony H Cincotta
Journal:  Diabetol Metab Syndr       Date:  2014-09-25       Impact factor: 3.320

9.  Time-of-Day-Dependent Effects of Bromocriptine to Ameliorate Vascular Pathology and Metabolic Syndrome in SHR Rats Held on High Fat Diet.

Authors:  Michael Ezrokhi; Yahong Zhang; Shuqin Luo; Anthony H Cincotta
Journal:  Int J Mol Sci       Date:  2021-06-07       Impact factor: 5.923

10.  Bromocriptine and insulin sensitivity in lean and obese subjects.

Authors:  L Bahler; H J Verberne; E Brakema; R Tepaske; J Booij; J B Hoekstra; F Holleman
Journal:  Endocr Connect       Date:  2016-10-10       Impact factor: 3.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.